Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix’s Proposed Merger with Akoya Biosciences

Kent Lake Partners, owning ~7.5% of Quanterix, opposes the proposed merger with Akoya Biosciences. They argue the deal undervalues Quanterix, unfairly benefits Akoya, involves excessive dilution and a $30M loan, and raises governance concerns. They urge shareholders to vote against the merger.